Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial

BACKGROUND: Cannabis use is an important risk factor for development of psychosis and further transition to schizophrenia. The prevalence of patients with psychosis and comorbid cannabis use (dual diagnosis) is rising with no approved specialized pharmacological treatment option. Cannabidiol, a cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasmussen, Jesper Østrup, Jennum, Poul, Linnet, Kristian, Glenthøj, Birte Y., Baandrup, Lone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364057/
https://www.ncbi.nlm.nih.gov/pubmed/34391393
http://dx.doi.org/10.1186/s12888-021-03395-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364057/
https://www.ncbi.nlm.nih.gov/pubmed/34391393
http://dx.doi.org/10.1186/s12888-021-03395-9

Ejemplares similares